

Vantas[®] (histrelin acetate) (Subcutaneous implant)

Document Number: IC-0135

Last Review Date: 05/01/2018

Date of Origin: 06/21/2011

Dates Reviewed: 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 5/2018

I. Length of Authorization

Coverage will be provided for 12 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [Pharmacy Benefit]:

- 50 mg implant: 1 per 12 months

B. Max Units (per dose and over time) [Medical Benefit]:

- 1 billable unit per 12 months

III. Initial Approval Criteria

Coverage is provided in the following conditions:

Advanced Prostate Cancer †

- Patient is 18 years or older

† FDA Approved Indication(s)

IV. Renewal Criteria

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the criteria in section III; **AND**
- Tumor response with stabilization of disease or decrease in size of tumor or tumor spread;
AND
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include:

V. Dosage/Administration

Indication	Dose
Prostate Cancer	One 50 mg implant inserted subcutaneously every 12 months

VI. Billing Code/Availability Information

Jcode:

J9225 – Histrelin implant (vantas), 50 mg: 1 billable unit = 50 mg

NDC:

Vantas 50 mg implant: 67979-0500-xx

VII. References

1. Vantas [package insert]. Malvern, PA; Endo Pharmaceuticals Solutions, Inc; June 2017. Accessed March 2018.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Histrelin acetate. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed March 2018.
3. First Coast Service Options, Inc. Local Coverage Determination (LCD): Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (L33685). Centers for Medicare & Medicaid Services, Inc. Updated on 3/05/2018 with effective date 3/15/2018. Accessed March 2018.
4. Novitas Solutions, Inc. Local Coverage Determination (LCD): Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (L34822). Centers for Medicare & Medicaid Services, Inc. Updated on 12/9/2014 with effective date 10/1/2015. Accessed March 2018.
5. National Government Services, Inc. Local Coverage Determination (LCD): Local Coverage Article for Luteinizing Hormone-Releasing Hormone (LHRH) Analogs – Related to LCD L33394 (A52453). Centers for Medicare & Medicaid Services, Inc. Updated on 7/22/2016 with effective date 8/1/2016. Accessed March 2018.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C61	Malignant neoplasm of prostate
Z85.46	Personal history of malignant neoplasm of prostate

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

Jurisdiction(s): N	NCD/LCD Document (s): L33685
https://www.cms.gov/medicare-coverage-database/search/lcd-date-search.aspx?DocID=L33685&bc=gAAAAAAAAAAAA	
Jurisdiction(s): H, L	NCD/LCD Document (s): L34822
https://www.cms.gov/medicare-coverage-database/search/document-id-search-results.aspx?Date=10/17/2017&DocID=L34822&bc=iAAAAAAAAAAAAAA%3d%3d&	
Jurisdiction(s): 6, K	NCD/LCD Document (s): A52453
https://www.cms.gov/medicare-coverage-database/search/document-id-search-results.aspx?DocID=A52453&bc=gAAAAAAAAAAAAAA%3d%3d&	

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC